Seres Therapeutics, Inc.
MCRBSeres Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $789,000.00, down 99.4% from fiscal 2023.
- Revenue
- +69.0%
- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
After hours trading: 1.25, up 0.81%, last trade Fri 7:35pm Eastern.
Follow MCRB
Alert me
Seres Therapeutics, Inc. (MCRB) Return on invested capital
Seres Therapeutics, Inc.'s return on invested capital over the twelve months to Sep 30, 2026 was −1,267.8%, down 1267.8 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −3,817.9% (fiscal 2015) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | 3,817.93 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ALLR Allarity Therapeutics, Inc. compare | 0.00% |
| ACTU Actuate Therapeutics, Inc. compare | 0.00% |
| ABOS Acumen Pharmaceuticals, Inc. compare | 0.00% |
| BSEM BioStem Technologies, Inc. compare | −7.07% |
| CTXR Citius Pharmaceuticals, Inc. compare | −58.7% |
| BOLT Bolt Biotherapeutics, Inc. compare | −154.8% |
| PLUR Pluri Inc. compare | −436.8% |
| MCRB Seres Therapeutics, Inc. | −1,267.8% |
| NCEL NewcelX Ltd. compare | — |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.06% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)